Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)

NCT: NCT04502316 · TERMINATED

NCT IDNCT04502316
StatusTERMINATED
Start Date2020-06-26
Completion2026-06-30
SponsorCVRx, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of this registry is to develop valid scientific evidence of the safety and benefit of Barostim Therapy in the commercial setting in patients with heart failure with reduced ejection fraction (HFrEF) that were recently implanted with the Barostim System.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑